CO2018003828A2 - Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-eno-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa - Google Patents

Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-eno-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa

Info

Publication number
CO2018003828A2
CO2018003828A2 CONC2018/0003828A CO2018003828A CO2018003828A2 CO 2018003828 A2 CO2018003828 A2 CO 2018003828A2 CO 2018003828 A CO2018003828 A CO 2018003828A CO 2018003828 A2 CO2018003828 A2 CO 2018003828A2
Authority
CO
Colombia
Prior art keywords
acid
difluoromethylene
cyclopent
ene
amino
Prior art date
Application number
CONC2018/0003828A
Other languages
English (en)
Spanish (es)
Inventor
Richard B Silverman
Kenji Takaya
Hoang V Le
Jose I Juncosa
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of CO2018003828A2 publication Critical patent/CO2018003828A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CONC2018/0003828A 2015-10-09 2018-04-10 Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-eno-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa CO2018003828A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562239330P 2015-10-09 2015-10-09
PCT/US2016/056245 WO2017062942A2 (en) 2015-10-09 2016-10-10 (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
CO2018003828A2 true CO2018003828A2 (es) 2018-07-19

Family

ID=58488679

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0003828A CO2018003828A2 (es) 2015-10-09 2018-04-10 Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-eno-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa

Country Status (19)

Country Link
US (3) US9670141B2 (enExample)
EP (1) EP3341355B1 (enExample)
JP (1) JP6841821B2 (enExample)
KR (1) KR102745965B1 (enExample)
CN (1) CN108137484B (enExample)
AU (1) AU2016334396B2 (enExample)
BR (1) BR112018007026B1 (enExample)
CL (1) CL2018000914A1 (enExample)
CO (1) CO2018003828A2 (enExample)
DK (1) DK3341355T3 (enExample)
ES (1) ES2825349T3 (enExample)
HU (1) HUE053429T2 (enExample)
IL (1) IL258516A (enExample)
LT (1) LT3341355T (enExample)
MX (1) MX380592B (enExample)
PE (1) PE20190349A1 (enExample)
PL (1) PL3341355T3 (enExample)
PT (1) PT3341355T (enExample)
WO (1) WO2017062942A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6591532B2 (ja) 2014-08-21 2019-10-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング MDM2−p53阻害剤としての新しいスピロ[3H−インドール−3,2’−ピロリジン]−2(1H)−オン化合物および誘導体
CN108137484B (zh) * 2015-10-09 2021-02-12 西北大学 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物
HUE054985T2 (hu) 2015-10-09 2021-11-29 Boehringer Ingelheim Int Spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és számrazékok, mint MDM2-P53 inhibitorok
KR20240110989A (ko) * 2017-02-08 2024-07-16 오비드 테라퓨틱스 인크. 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들
US10653652B2 (en) 2018-02-08 2020-05-19 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction
US11771671B2 (en) 2018-02-08 2023-10-03 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
AU2019243586A1 (en) * 2018-03-29 2020-10-15 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders
US10822301B2 (en) * 2018-04-12 2020-11-03 Northwestern University 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase
JP7475055B2 (ja) 2018-05-25 2024-04-26 ノースウェスタン ユニバーシティ (s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸の合成法
WO2019236938A1 (en) 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
US11203596B2 (en) 2019-02-25 2021-12-21 Northwestern University Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity
US11078153B2 (en) 2019-04-03 2021-08-03 Northwestern University 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase
CN110935495B (zh) * 2019-11-29 2021-02-23 中国科学院电子学研究所 Gaba和电生理微纳同步传感检测芯片及其制备方法
US11993569B2 (en) 2020-01-23 2024-05-28 Northwestern University 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases
EP4301724A4 (en) * 2021-03-03 2025-05-28 Northwestern University (S)-3-AMINO-4,4-DIHALOCYCLOPENT-1-CARBOXYLIC ACID AS SELECTIVE INACTIVATORS OF HUMAN ORNITHINE AMINOTRANSFERASE
US20250171397A1 (en) * 2022-02-27 2025-05-29 Northwestern University (3s,4r)-3-amino-4-(difluoromethyl)cyclopent-1-ene-1-carboxylic acid and related compounds as selective inactivators of ornithine aminotransferase
KR20250034134A (ko) * 2022-07-06 2025-03-10 오비드 테라퓨틱스 인크. 암 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸렌일)사이클로펜트-1-엔-1-카르복실산의 사용
KR20250145687A (ko) * 2023-02-17 2025-10-13 오비드 테라퓨틱스 인크. 류마티스 관절염의 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복시산의 용도
US20240285565A1 (en) 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes
AU2024220869A1 (en) 2023-02-17 2025-09-04 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis
IL322802A (en) 2023-02-17 2025-10-01 Ovid Therapeutics Inc Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of gastrointestinal disorders and as an immunomodulatory agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
IL177609A (en) * 2006-08-21 2015-11-30 Yaron Ilan Use of gobacoline or its analogue to produce a drug to treat liver carcinoma
CA2790820A1 (en) * 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
AR087700A1 (es) * 2011-08-30 2014-04-09 Gilead Sciences Inc Inhibidores de aldh-2 en el tratamiento de adicciones
CN108137484B (zh) * 2015-10-09 2021-02-12 西北大学 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物

Also Published As

Publication number Publication date
DK3341355T3 (da) 2020-10-26
IL258516A (en) 2018-05-31
EP3341355A4 (en) 2019-04-10
KR20180052782A (ko) 2018-05-18
HK1253002A1 (zh) 2019-06-06
MX2018004302A (es) 2018-11-09
ES2825349T3 (es) 2021-05-17
BR112018007026B1 (pt) 2022-06-21
AU2016334396A1 (en) 2018-04-19
US20180271816A1 (en) 2018-09-27
US9993449B2 (en) 2018-06-12
HUE053429T2 (hu) 2021-07-28
PT3341355T (pt) 2020-10-21
US20170101364A1 (en) 2017-04-13
CA3001330A1 (en) 2017-04-13
PE20190349A1 (es) 2019-03-07
WO2017062942A3 (en) 2018-03-01
KR102745965B1 (ko) 2024-12-20
US9670141B2 (en) 2017-06-06
MX380592B (es) 2025-03-12
EP3341355A2 (en) 2018-07-04
LT3341355T (lt) 2020-11-10
JP2018531941A (ja) 2018-11-01
BR112018007026A2 (pt) 2018-10-16
CN108137484A (zh) 2018-06-08
AU2016334396B2 (en) 2021-04-08
PL3341355T3 (pl) 2021-03-08
CL2018000914A1 (es) 2018-08-31
EP3341355B1 (en) 2020-09-30
WO2017062942A2 (en) 2017-04-13
US20170239202A1 (en) 2017-08-24
CN108137484B (zh) 2021-02-12
JP6841821B2 (ja) 2021-03-10

Similar Documents

Publication Publication Date Title
CL2018000914A1 (es) Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
LT3303330T (lt) 4-hidroksi-3-(heteroaril)piridin-2-ono apj agonistai, skirti panaudoti širdies ir kraujagyslių sutrikimų gydymui
CR20160553A (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
HUE059747T2 (hu) Eljárások rendellenes, akaratlan mozgással járó zavarok kezelésére
IL252981A0 (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
DK3261726T3 (da) Sammensætning til behandling af acne
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
PL3157534T3 (pl) Inhibitory acetylocholinesteraz w leczeniu stanów dermatologicznych
ZA201701392B (en) Inhibitors of a-amino-b-carboxymuconic acid semialdehyde decarboxylase
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EA201790912A1 (ru) Гетероциклическое соединение
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
DK3151853T3 (da) Glutaminsyre-decarboxylase (GAD) til anvendelse ved behandling af en autoimmun sygdom
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
FI20145484A7 (fi) Anodiliejun hydrometallurginen käsittely
BR112017009289A2 (pt) métodos de administrar composições de amantadina
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
EA201691057A1 (ru) Новые способы лечения нейродегенеративных заболеваний
EP3311767A4 (en) HIGH FREQUENCY TREATMENT TOOL
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
FR3023177B1 (fr) Procede de preparation de co-cristaux par evaporation flash